Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 28, Number 7—July 2022
Research Letter

Persistent SARS-CoV-2 Alpha Variant Infection in Immunosuppressed Patient, France, February 2022

Slim FouratiComments to Author , Guillaume Gautier, Myriam Chovelon, Alexandre Soulier, Melissa N’Debi, Vanessa Demontant, Céline Kennel, Christophe Rodriguez, and Jean-Michel Pawlotsky
Author affiliations: Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France (S. Fourati, A. Soulier, M. N’Debi, V. Demontant, C. Rodriguez, J.-M. Pawlotsky); William Morey General Hospital, Chalon-sur-Saône, France (G. Gautier, M. Chovelon, C. Kennel)

Suggested citation for this article

Abstract

We describe persistent circulation of SARS-CoV-2 Alpha variant in an immunosuppressed patient in France during February 2022. The virus had a new pattern of mutation accumulation. The ongoing circulation of previous variants of concern could lead to reemergence of variants with the potential to propagate future waves of infection.

Immunosuppressed patients can have prolonged SARS-CoV-2 infection (1). Studies have reported the occurrence and selection of multiple mutations in the spike glycoprotein sequence in immunosuppressed patients with persistent SARS-CoV-2 infections (26). To date, intrahost mutations have been described essentially in the ancestral wild-type SARS-CoV-2 virus (3,58), especially during prolonged infection with variants of concern (VOCs) (9). Additional SARS-CoV-2 mutations in immunocompromised persons could enable increased virus transmissibility and immune evasion, shaping the emergence of new VOCs. We describe a new mutation accumulation pattern in SARS-CoV-2 Alpha virus in an immunosuppressed patient.

Figure

Timeline of SARS-CoV-2 diagnostic tests, hospitalizations, booster vaccination, and treatments for an immunosuppressed patient with persistent SARS-CoV-2 Alpha variant infection, France, 2022. RCHOP, combination therapy of rituximab, cyclophosphamide, doxorubicine, vincristine, and prednisone; RDHAC, combination therapy of rituximab, cytarabine, dexamethasone, and carboplatine.

Figure. Timeline of SARS-CoV-2 diagnostic tests, hospitalizations, booster vaccination, and treatments for an immunosuppressed patient with persistent SARS-CoV-2 Alpha variant infection, France, 2022. RCHOP, combination therapy of rituximab, cyclophosphamide, doxorubicine, vincristine,...

An 84-year-old woman with evolutive mantle cell lymphoma who was receiving maintenance rituximab and lenalidomide treatment was admitted to the hospital on May 17, 2021. She had asthenia, fever, and hypoxia (93% oxygen saturation). At admission (day 0), she tested positive for SARS-CoV-2 RNA (Figure). She had received 2 vaccine doses 84 and 66 days before admission. She did not have respiratory symptoms, but a chest computed tomography scan showed ground-glass opacities in her lungs. The patient was hospitalized and treated with corticosteroids for 10 days. She tested SARS-CoV-2–positive again on August 26, day 101 after her initial positive test. On September 27 (day 133), she tested SARS-CoV-2–negative and was considered virologically cured. She received a vaccine booster (third) dose at day 164 and a fourth dose on day 201, but we did not detect spike receptor binding domain antibodies at days 133, 201, or 210.

Beginning in October 2021, the patient experienced intermittent fever and diarrhea because her lymphoma progressed, as shown by an abdominal computed tomography scan; she was started on a second-line treatment with ibrutinib (Figure). She was hospitalized again in early January 2022 (day 208) after clinicians discovered an evolutive lymph node mass. At admission, she tested SARS-CoV-2–positive despite the absence of COVID-19 symptoms. SARS-CoV-2 RNA levels from nasopharyngeal swab samples were high; cycle threshold values were 19 on day 208, 18 on day 228, and 22 on day 234.

At days 0, 101, 208, and 234, multiplex mutation-specific reverse transcription PCR revealed the absence of spike amino acid mutations E484Q, E484K, and L452R, and K417N was not detected on days 208 and 234, suggesting that the patient was not infected with Delta or Omicron variants, the 2 dominant variants in France at the time. These results suggested that the patient was infected with the Alpha variant, which was the dominant variant circulating when she first tested positive.

To determine whether the patient was infected with a new strain or reinfected with the same persistently replicating variant, we performed whole-genome sequencing on samples collected on days 208 (January 11, 2022) and 228 (January 31, 2022) and identified lineage B.1.1.7 (Alpha variant). Older samples were not available for sequencing. Our analysis revealed the presence of amino acid substitutions and mutations in addition to characteristics of the Alpha variant, including mutations in open reading frame (ORF) 1a (nonstructural protein 3, n = 4), spike protein (n = 6), matrix protein (n = 1), envelope protein (n = 2), ORF3a (n = 1), and ORF7 (n = 2) (Appendix Figure).

The SARS-CoV-2 mutational pattern in this immunosuppressed patient adds several new mutations to the Alpha variant characteristic. Although earlier samples were not available for sequencing, mutations in later samples align with an ongoing selection process. The mutations we observed share similarities with those observed in other VOCs and variants of interest, pointing to evolutionary convergence, such as spike del241–247, which also is found in part in the Beta variant. Several mutations that likely play a role in immune evasion were selected in the spike nucleocapsid terminal domain (e.g., K77E, S248F, and del14–18) and receptor-binding domain (L452M). These mutations have rarely been reported in isolates submitted to GISAID (https://www.gisaid.org), suggesting that, when considered individually, they could be maladaptive.

In January 2022, the Alpha variant was no longer circulating in France, according to strains submitted to GISAID. Our case highlights the potential for persistence of supposedly extinct SARS-CoV-2 variants that might cause prolonged infection in immunocompromised patients and acquire adaptive mutations that confer increased transmissibility, antigenic divergence, and reduced pathogenicity, with obvious public health implications (1,3). Similar cases likely exist in other parts of the world because SARS-CoV-2 genome sequencing and reporting to GISAID are far from exhaustive.

Omicron-infected patients not immunized against older variants appear to mount a weak or no neutralizing response against variants that preceded Omicron, including VOCs (R.K. Suryawanshi et al., unpub. data, https://doi.org/10.1101/2022.01.13.22269243). Because the next dominant variant could emerge from a variant other than Omicron, ongoing circulation of older VOCs could feed reemergence of variants that eliminate Omicron, particularly in unvaccinated populations, emphasizing the crucial role of vaccination to prevent new SARS-CoV-2 waves.

In conclusion, this report highlights the need to reinforce precautions to avert nosocomial and community transmission involving immunocompromised patients, who might shed older SARS-CoV-2 variants longer. Prospective genomic surveillance for SARS-CoV-2 variants is needed in persons with prolonged infection, particularly in countries with many immunocompromised persons, such as countries with a high HIV prevalence and low vaccination rates.

Prof. Fourati is a researcher at the University of East Paris, Créteil, France. He is also a clinical virologist in the Department of Microbiology, Henri Mondor Hospital, Créteil, France. His primary research interests include viral evolution and adaptation, viral hepatitis, and respiratory viruses, including SARS-CoV-2.

Top

Acknowledgments

Funding for this study was provided by the ministry of health of France as part of the surveillance program for SARS-CoV-2 genomic evolution.

S.F. has served as a speaker for GlaxoSmithKline, Abbvie, and Abbott Diagnostics. C.R. has served as an advisor and speaker for Illumina and Vela Diagnostics. J.-M.P. has served as an advisor and speaker for Abbvie, Gilead, Merck, Assembly Biosciences, and Arbutus. The remaining authors have no conflicts of interest to disclose.

Top

References

  1. Corey  L, Beyrer  C, Cohen  MS, Michael  NL, Bedford  T, Rolland  M. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385:5626. DOIPubMedGoogle Scholar
  2. Wang  Y, Wang  D, Zhang  L, Sun  W, Zhang  Z, Chen  W, et al. Intra-host variation and evolutionary dynamics of SARS-CoV-2 populations in COVID-19 patients. Genome Med. 2021;13:30. DOIPubMedGoogle Scholar
  3. Khateeb  D, Gabrieli  T, Sofer  B, Hattar  A, Cordela  S, Chaouat  A, et al. SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection. PLoS Pathog. 2022;18:e1010242. DOIPubMedGoogle Scholar
  4. Weigang  S, Fuchs  J, Zimmer  G, Schnepf  D, Kern  L, Beer  J, et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun. 2021;12:6405. DOIPubMedGoogle Scholar
  5. Cele  S, Karim  F, Lustig  G, San  JE, Hermanus  T, Tegally  H, et al.; COMMIT-KZN Team. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30:154162.e5. DOIPubMedGoogle Scholar
  6. Choi  B, Choudhary  MC, Regan  J, Sparks  JA, Padera  RF, Qiu  X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:22913. DOIPubMedGoogle Scholar
  7. Pérez-Lago  L, Aldámiz-Echevarría  T, García-Martínez  R, Pérez-Latorre  L, Herranz  M, Sola-Campoy  PJ, et al.; On Behalf Of Gregorio Marañón Microbiology-Id Covid Study Group. Different within-host viral evolution dynamics in severely immunosuppressed cases with persistent SARS-CoV-2. Biomedicines. 2021;9:808. DOIPubMedGoogle Scholar
  8. Avanzato  VA, Matson  MJ, Seifert  SN, Pryce  R, Williamson  BN, Anzick  SL, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183:19011912.e9. DOIPubMedGoogle Scholar
  9. Truffot  A, Andréani  J, Le Maréchal  M, Caporossi  A, Epaulard  O, Germi  R, et al. SARS-CoV-2 variants in immunocompromised patient given antibody monotherapy. Emerg Infect Dis. 2021;27:27258. DOIPubMedGoogle Scholar

Top

Figures

Top

Suggested citation for this article: Fourati S, Gautier G, Chovelon M, Soulier A, N’Debi M, Demontant V, et al. Persistent SARS-CoV-2 Alpha variant infection in immunosuppressed patient, France, February 2022. Emerg Infect Dis. 2022 Jul [date cited]. https://doi.org/10.3201/eid2807.220467

DOI: 10.3201/eid2807.220467

Original Publication Date: May 05, 2022

Table of Contents – Volume 28, Number 7—July 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Slim Fourati, Henri Mondor Hospital, 51 av du Marechal de Lattre de Tassigny, Créteil 94010, France

Send To

10000 character(s) remaining.

Top

Page created: April 25, 2022
Page updated: May 05, 2022
Page reviewed: May 05, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external